Join Cell & Gene Therapy Manufacturing Asia 2022
The ONLY event in Asia connecting you to Asia’s key cell & gene therapy players with representations from R&D & ManufacturingDownload Brochure
Showcase Your Solutions
Thought Leadership, Product Showcase, Lead Generation, Branding and Other Opportunities Available!Download Sponsorship Prospectus
Branding And Networking Opportunities On Our App!
Explore Endless Learning & Networking Opportunities On Our Virtual Event Platform!Download Brochure
Globally, the stem cell therapy market is expected to be worth $180 billion by 2030. The largest number of marketed cell therapy products is used for the treatment of notably non-healing wounds / skin (46%) and muscular-skeletal injuries (35%). This trend will change as more and stem cell therapy products for cancer and heart disease complete their clinical trials and are approved for market release.
The Asia-Pacific stem cell market was valued at US $7.10 billion in 2014 and is projected to increase to US $18.71 billion by 2018 at a CAGR of 27.3% for the period. Asia-Pacific is expected to be the fastest growing segment with a CAGR of over 25.0% due to rising contract research outsourcing and medical tourism. Adult stem cell leads the market due to low contamination during sub-culture and expansion, relatively low labor production and compatibility with the human body. Just the Induced pluripotent stem cells (IPSc’s are expected to report revenue of over USD 4.5 billion by 2020, on account of analogous nature of its origin.
With the continued growth of medical tourism hubs like India, Singapore, and Thailand, Asia is expected to maintain its place as the epicentre of stem cell research and therapy. These opportunities include contract research outsourcing and rising patient population with neurological and other chronic conditions in the region. Japan, Singapore and South Korea are the frontrunners and are set to dominate the APAC stem cell market in the coming year.
Cell & Gene Therapy Manufacturing Asia 2022 is bringing together Asia’s best of best in cell and gene therapy development and manufacturing. This will be the most targeted and the only regional conference that will attract cell therapy companies in South Korea, Japan, China, India, Singapore, Taiwan and the rest of Asia to discuss and debate on best practices and innovations in this space.
John Rossi Kite Pharma
Hemant Chamne Immuneel Therapeutics Pvt Ltd
Gil Carrasquinho Santen Pharmaceutical
Chen Yi Jerry Kuo UWell Biopharma
Prof Hideyuki Okano Keio University Graduate School of Medicine
Steven Feldman Stanford Center for Cancer Cell Therapy
Zhang Yu Aeon Therapeutics
Andreas Weiler Novartis
Sandy Qlintang PT Kalbe
Yen Choo Progenitor Therapeutics
Krishnendu Roy Georgia Institute of Technology
Sebastian Carnel Takeda
Jeong Hoon Han Eutilex
Karen Wen GenomeFrontier Therapeutics
Sung Ho Hahm Rophibio Inc
Max Chai Maria Von
Chris Tsai UnicoCell Biomed
Udaykumar Kolkundkar Stempeutics Research Pvt Ltd
Shashwati Basak Immuneel Therapeutics Ltd
Jeong Hoon Han Eutilex
Position your products & services in front of senior decision-makers from both the global biopharmaceutical industry at the Cell & Gene Therapy Manufacturing 2022. You get exclusive one-to-one access to key stakeholders to present your expertise through a variety of available thought leadership, branding and exhibitor packages.
Get in touch with us about your needs today!